Influence of a randomized monoclonal or polyclonal program of therapy on cytomegalovirus infection in kidney transplantation.
Raffaele
P
P
Transplantation Unit, E. Herriot Hospital, Lyon, France.
Pouteil-Noble
C
C
Lefrancois
N
N
Bosshard
S
S
Betuel
H
H
Aymard
M
M
Dubernard
J M
JM
Touraine
J L
JL
D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D000961:Antilymphocyte Serum / Q000008:administration & dosage*; D003586:Cytomegalovirus Infections / Q000150:complications*; D006084:Graft Rejection; D006680:HLA Antigens / Q000276:immunology; D006648:Histocompatibility; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods; D016030:Kidney Transplantation / Q000379:methods*; D016853:Muromonab-CD3
D000911:Antibodies, Monoclonal; D000961:Antilymphocyte Serum; D006680:HLA Antigens; D016853:Muromonab-CD3